-
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
•
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely cease enrollment in a Phase II trial for the T-cell stimulatory pathways inhibitor acazicolcept in systemic lupus erythematosus (SEL). This move allows for an early assessment of the trial data and enables Alpine to redirect…
-
Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List
•
Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel management and separate payment, focusing on those added to the National Reimbursement Drug List (NRDL) through negotiations this year. A total of 74 drugs fall under “dual channel” management, with 36 designated for separate payment.…
-
J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC
•
The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J; NYSE: JNJ) application for Rybrevant (amivantamab), a bispecific antibody, in combination with lazertinib, a tyrosine kinase inhibitor (TKI), for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon…
-
Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products
•
The Hunan Healthcare Security Administration has published a list of 226 drugs to be included under the “dual channel” single-line payment management system, which includes 43 newly added products from the 2023 National Reimbursement Drug List (NRDL) negotiations. The targeted drugs are characterized by high clinical value, urgent need, and…
-
Shanghai Fosun to Exclusively Commercialize Generic Entresto in China
•
Nanjing F&S Pharmatech Co., Ltd has officially launched its generic version of Novartis’s heart failure therapy Entresto (sacubitril, valsartan) in China, with exclusive commercialization rights held by Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196). Entresto, a breakthrough treatment for chronic heart failure, was first approved in China in 2017…
-
Shouyao Holdings Receives Ethical Approval for Phase III Study of ALK Inhibitor SY-3505
•
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received ethical approval to conduct a pivotal Phase III clinical study for its third-generation anaplastic lymphoma kinase (ALK) inhibitor, SY-3505. The study is a randomized, controlled, multi-center trial designed to assess the efficacy and safety of SY-3505…
-
Hengrui Medicine-Backed Nanjing Tianyinshan Hospital Opens as Class 3A Oncology Specialist Center
•
Nanjing Tianyinshan Hospital, a private Class 3A oncology specialist hospital invested in by Hengrui Medicine (SHA: 600276), commenced operations on December 22. The hospital is headed by Professor Qin Shukui, a prominent figure in the field of oncology. Situated in the Nanjing Jiangning High Tech Zone, the hospital spans a…
-
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US
•
China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of its Category 1 chemical drugs in China and the United States, with indications spanning cancer, kidney diseases, and infectious diseases. JMKX003801, approved for study in China for severe infections caused by Gram-negative bacteria, has demonstrated…
